<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476060</url>
  </required_header>
  <id_info>
    <org_study_id>DDRC85-13</org_study_id>
    <nct_id>NCT00476060</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Transplantation in Decompensated Cirrhosis</brief_title>
  <official_title>Autologous Mesenchymal Stem Cell Transplantation in Patients With Decompensated Cirrhosis: A Randomized Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tehran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tehran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard treatment for decompensated cirrhosis is liver transplantation, however, it has&#xD;
      several limitations. Recent animal studies suggest that bone marrow stem cell transplantation&#xD;
      can lead to regression of liver fibrosis. The investigators have already completed the phase&#xD;
      1 study of bone marrow mesenchymal stem cell (MSC) transplantation in 4 patients with&#xD;
      cirrhosis. The procedure was safe, and feasible, and led to somewhat promising results&#xD;
      (Mohamadnejad M, et al. 2006; Submitted for publication). The aim of this study is to find&#xD;
      efficacy of this new treatment strategy in the setting of a multicenter, randomized&#xD;
      placebo-controlled trial in 50 patients with decompensated cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard treatment for decompensated cirrhosis is liver transplantation, however, it has&#xD;
      several limitations, including small donor pool, long waiting list, and several&#xD;
      complications. Recent animal studies suggest that bone marrow stem cell transplantation can&#xD;
      lead to regression of liver fibrosis. The investigators have already completed the phase 1&#xD;
      study of bone marrow mesenchymal stem cell (MSC) transplantation in 4 patients with&#xD;
      cirrhosis. The procedure was safe, and feasible, and led to somewhat promising results&#xD;
      (Mohamadnejad M, et al. 2006; Submitted for publication). The aim of this study is to find&#xD;
      efficacy of this new treatment strategy in the setting of a multicenter, randomized placebo&#xD;
      controlled trial. After assignment of the written informed consent, thirty six patients with&#xD;
      decompensated cirrhosis will be enrolled, and will be randomized by block randomization into&#xD;
      treatment or placebo arm. All the enrolled patients will be in the waiting list of liver&#xD;
      transplantation. In the treatment arm bone marrow of the patients will be aspirated, and&#xD;
      autologous bone marrow mesenchymal stem cells will be cultured, and then will be infused&#xD;
      through a peripheral vein. Also, the corresponding placebo will be infused for the placebo&#xD;
      group. The patients will be followed up for 1 year after performing the procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MELD score, quality of life, liver volume, histological improvement (In a subset of patients with evidences of clinical and biochemical improvement, follow up liver biopsy will be performed at the end of follow up).</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality, tracking the infused cells in the patients' bodies.</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous mesenchymal stem cell transplantation</intervention_name>
    <description>Arm A: 300 million cells will be infused one time through a peripheral vein/// Arm B: Infusion of placebo one time through a peripheral vein</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cirrhosis (diagnosed by clinical, biochemical, sonographic, and histologic evidences&#xD;
             of cirrhosis) (Patients will have histological documentation of cirrhosis before&#xD;
             enrollment. However, for those with evidences of severe coagulopathy liver biopsy may&#xD;
             not be performed)&#xD;
&#xD;
          -  Evidences of decompensated liver disease at screening (e.g. child class B, or C)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of active hepatic encephalopathy&#xD;
&#xD;
          -  Refractory ascites&#xD;
&#xD;
          -  Evidences of active autoimmune liver disease (e.g. gamma globulin of more than 2 times&#xD;
             of upper limit of normal, and ALT &gt; 3 times normal in patients with autoimmune&#xD;
             hepatitis)&#xD;
&#xD;
          -  Hepatocellular carcinoma or other malignancies&#xD;
&#xD;
          -  Active infectious disease&#xD;
&#xD;
          -  Presences of severe underlying cardiac, pulmonary, or renal disease&#xD;
&#xD;
          -  Alcohol use in the last 3 months before screening&#xD;
&#xD;
          -  Use of hepatotoxic drugs in the last 3 months before screening&#xD;
&#xD;
          -  Unwilling to assign the informed consent&#xD;
&#xD;
          -  Presence of significant extrahepatic biliary disease (e.g. CBD stone, PSC, etc.)&#xD;
&#xD;
          -  Positive HIV ab&#xD;
&#xD;
          -  Positive HBsAg with detectable HBV DNA PCR&#xD;
&#xD;
          -  Positive HCV Ab with detectable HCV RNA PCR&#xD;
&#xD;
          -  Active thrombosis of the portal or hepatic veins&#xD;
&#xD;
          -  Serum Cr &gt; 1.8 mg/dL at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Malekzadeh, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Digestive Disease Research Center, Medical Sciences/ University of Tehran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ardeshir Ghavamzadeh, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hematology, Oncology, and BMT research center, Medical Sciences/University of Tehran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehdi Mohamadnejad, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Digestive Disease Research Center, Medical Scineces/ University of Tehran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kamran Alimoghaddam, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology, Oncology, and BMT research center, Medical Sciences/University of Tehran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Digestive Disease Research Center, Shariati Hospital</name>
      <address>
        <city>Tehran</city>
        <zip>14117-13135</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>May 16, 2007</study_first_submitted>
  <study_first_submitted_qc>May 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2007</study_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Reza Malekzadeh</name_title>
    <organization>Digestive Disease Research Center, Medical Sciences/ University of Tehran</organization>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>Bone marrow</keyword>
  <keyword>Mesenchymal stem cell</keyword>
  <keyword>MELD score</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

